Sitemap

74 Years of Galenika: Investments And Business Success In The First Half Of 2019

CorD Recommends

Belgrade’s Hotel Jugoslavija Sold, Sparks Redevelopment Controversy

Belgrade's iconic Hotel Jugoslavija, located in Serbia's...

Gold Prices Reach Record Highs Amid Central Bank Acquisition Spree

Gold prices have soared to all-time highs,...

AstraZeneca Celebrates Inauguration of New Office in Belgrade and 25th Anniversary Milestone

AstraZeneca, a global leader in healthcare innovation,...

EU Passes Landmark Media Freedom Law

The European Council has adopted a groundbreaking law aimed at safeguarding media freedom, pluralism, and editorial independence within the...

Scholz Champions Western Balkans’ Path to Membership

German Chancellor Olaf Scholz, in Slovenia, advocated for quickening the EU accession for the Western Balkans, underlining the importance...

Wiener Städtische Insurance company is the winner of Dobročinitelj (Benefactor) award

The company Wiener Städtische Insurance received the Dobročinitelj (Benefactor) award for socially responsible activities implemented during 2021, 2022 and...

CEB Grants €1.3 Billion Loans to Boost Social Sectors in 11 Countries

The Council of Europe Development Bank (CEB) has sanctioned loans totaling €1.3 billion for 11 member countries, including Serbia...

Serbia Advances in Renewable Energy with Pupin Wind Park Financing

In a significant stride towards renewable energy adoption, Serbia has finalized the financial arrangements for the Pupin Wind Park,...

Demonstrating the vision and readiness to adapt to the latest business trends and market demands, the domestic pharmaceutical company Galenika a.d., which became part of the international NC Group, one of the largest pharmaceutical company in Latin America, in the first half of 2019 reached the gross sales of its products in the Serbian market of 27.4 million euros, an increase of 13% compared to the same period in 2018 and thus has made a significant shift from fourth to the second place according to the market share in Serbia*.

In the first half of 2019, Galenika also increased the production of its product range by as much as 43.7% compared to the same period in 2018. This year, the company has so far obtained licenses for placing 6 products on the market, which has expanded the portfolio of Galenika in the product-groups used in the treatment of cardiovascular diseases and hypertension, diabetes, antidepressant and dermatics.

The plan for the current year is the granting of a licensing for a total of 10 products, where among the new products there will also be those who represent novelty in therapy, both in the application of a different pharmaceutical form in comparison with previous practice, as well as for greater safety in relation to other products from the same pharmacological group on the market.

“In order to create a modern and competitive company, and with our strong commitment to investing in development, the company raises internal capacities through educational programs and the most up-to-date employee training. Additionally, in the year when Galenika is proudly celebrating the 74th business jubilee, we have invested in state-of-the-art software for advanced management of all business processes – SAP S4HANA Cloud, which made our company one of the pioneers of digital transformation in Central and Eastern Europe. Current investments are just beginning on our decisive road ahead, determined to Galenika’s again become the leader in the region,” said Ricardo Vian Marques, Executive Director for Operational Affairs of Galenika.

As Marques noted, in the next three years Galenika expects a trend of doubling sales in the Serbian market.

As a company committed to improving the health and quality of life of its patients and beneficiaries of products, with the aim of further development of therapy in the areas of cardiovascular diseases, central nervous system diseases and antibiotics, Galenika launched the work of its Scientific Committees, whose members are some of the most eminent medical experts in Serbia.

In accordance with its mission, through implementing the latest knowledge in the field of pharmaceutical technology, Galenika continued its development activities within its Institute for Research and Development, and after 8 years, a new product was launched – Flonivin plus.

Related Articles

Ricardo Vian Marques, General Manager, Galenika

Focus On Quality And Growth Drivers

Despite the challenges of global circumstances in 2023, Galenika successfully ensured the production and distribution of its products to all markets where it operates....

Galenika-Fitofarmacija

Pillar Of Support To Domestic And European Farmers

With 16 registered products that are harmonised with European legislations, phytopharmaceuticals company Galenika-Fitofarmacija a.d. (JSC) is present on 28 markets, 19 of which are...

Carlos Puglia, Galenika Executive Director For Sales And Marketing

We Are Ready For Global Goals

As part of Grupo NC, one of the largest conglomerates in Brazil, Galenika is a company that operates on the global market. Its focus...

Milorad Ilić, Galenika

Pharmaceutical Operations In The EU

Over the course of the previous three years, Galenika has undergone an intensive period of investment and transformation, thanks to which it has repositioned...

Ljiljana Topić, Director, Galenika Pharmacia

Nurturing It’s Own Leadership Position

Galenika Pharmacia produces more than 50 different medical devices - sterile and non-sterile compresses, plaster strips, bandaid plasters, bandages and sanitary materials, vehicle first...

Ricardo Vian Marques, General Manager, Galenika a.d. Beograd

Future-Orientated Company

Over the course of 2020, Galenika continued its trend from the previous year by growing faster than the market, more than 50% faster. It...

Ljiljana Topić, Director, Galenika Pharmacia

We’re Here When Times Are Hardest

Galenika Pharmacia is a factory that produces complete sanitary consumables – from compresses, gauzes and bandages, via disinfectants, to surgical masks that have become...

75 Years Of Galenika

In the jubilee year, Galenika a.d. Belgrade records constant growth in all segments of its business. In the first half of 2020, Galenika achieved...